←
Michael Ostacher, MD, MPH23,238 posts
Michael Ostacher, MD, MPH avatar

Michael Ostacher, MD, MPH

@RecoveryDoctor

Professor of Psychiatry & Beh Sciences @StanfordMed decreasing stigma/increasing evidence/improving care. Food tweets. Digital Ed @BMJMentalHealth Opinions mine

◷ Joined January 2013▧ 1,867 Photos and videos
Michael Ostacher, MD, MPH avatar
Michael Ostacher, MD, MPH@RecoveryDoctor·14 Mar 2023

Just had a patient tell me today that my prescribing acamprosate saved his life. Hasn't drank since. "I just don't think about it anymore." Never had someone taking gabapentin tell me that, so just a reminder to all of you out there to follow the data and to watch your biases.😀

Robert Howard avatar
⟳ Michael Ostacher, MD, MPH retweeted
Robert Howard@ProfRobHoward·Nov 17

The First Rule of Critical Psychiatry is, of course and as everyone should know, that nobody is allowed to criticise critical psychiatrists.

My response to John Goulder's hit-piece against me & other critics of antidepressants. It presents itself as 'an account of a quaint, historical controversy..whereas it is actually a partisan intervention in a contemporary and ongoing debate.' joannamoncrieff.wordpress.co…

Michael Ostacher, MD, MPH avatar
Michael Ostacher, MD, MPH@RecoveryDoctor·Nov 17

Says the woman whose current career is a hit-piece. (It was a pretty balanced and thoughtful piece by Goulder, you all should read it.)

My response to John Goulder's hit-piece against me & other critics of antidepressants. It presents itself as 'an account of a quaint, historical controversy..whereas it is actually a partisan intervention in a contemporary and ongoing debate.' joannamoncrieff.wordpress.co…

Amir Sariaslan avatar
⟳ Michael Ostacher, MD, MPH retweeted
Amir Sariaslan@AmirSariaslan·Nov 17

In our latest paper (w/ @seenafazel & @RongqinYu), we have redeveloped the Oxford Mental Illness and Suicide tool (OxMIS) as diagnosis-specific models for schizophrenia-spectrum disorders (n = 48 373) and bipolar disorder (n = 61 684) using nationwide Swedish data, and validated them externally in equivalent data from Finland (n = 52 117 and 30 444, respectively). Discrimination was moderate for schizophrenia-spectrum disorders and good for bipolar disorder, calibration was generally good, and both models showed greater net benefit than treat-all or treat-none strategies at lower risk thresholds. Interestingly, we did not find that adding sociodemographic predictors improved predictive performance. Full-text: mentalhealth.bmj.com/content…

Post attachmentPost attachmentPost attachmentPost attachment
Crémieux avatar
⟳ Michael Ostacher, MD, MPH retweeted
Crémieux@cremieuxrecueil·Nov 16

I updated my post on GLP-1s and muscle mass loss! A new cohort study found that, at one year, people taking semaglutide tended to lose ~80% of weight as fat, versus 82% for tirzepatide. Both were comparable to just dieting.

Post attachment
Crémieux avatar
⟳ Michael Ostacher, MD, MPH retweeted
Crémieux@cremieuxrecueil·Nov 11

Two things: 1. No, smoking is down. 2. Vaping is safer than smoking.

Post attachment

Gen Z fueling tobacco sales as wild claims cigarettes are 'healthier' than vaping go viral: 'plant-based alternative' trib.al/tsOeuG2

Post attachment
Michael Ostacher, MD, MPH avatar
Michael Ostacher, MD, MPH@RecoveryDoctor·Nov 11

My favorite Marsha Linehan anecdote: One of my research assistants got into two PhD programs in psychology, one at UW with Linehan, and and chose not to go there. (It was a hard decision.) She called Dr. Linehan to let her know that she was going to the other program. Linehan hung up on her. Bless her for developing a treatment to help people just like her. Changed treatment forever. RIP.

Marsha Linehan was most validating therapist I've known but also most demanding. Her "dialectic" means accepting what person feels, but expecting major efforts toward behavioral change. Both essential. Validation alone justifies not changing. High expectation alone always fails

Glenn Sullivan avatar
⟳ Michael Ostacher, MD, MPH retweeted
Glenn Sullivan@drglennsullivan·Nov 11

Marsha M. Linehan, Ph.D. May 5, 1943 – November 10, 2026 She gave hope to those whom others thought hopeless. Requiescat in pace.

Post attachment
Adam Cifu avatar
⟳ Michael Ostacher, MD, MPH retweeted
Adam Cifu@adamcifu·Nov 10

It is responses like these that keep me here. Thanks @TamarHaspel

This is demonstrably false. In 40 years, there has not been a single lifestyle intervention that, in trials, worked for long-term weight loss. GLP-1 users lose weight *and* improve their diet. You guys had nearly a half-century to come up with something, and you didn't.

James Murrough avatar
⟳ Michael Ostacher, MD, MPH retweeted
James Murrough@JMurrough·Nov 10

Nice commentary on a key issue in psychiatric and medical clinical trial design. Functional unblinding and expectancy are not unique to psychedelics, but psychedelic-like drugs are particularly vulnerable to them.

A commentary published in JCP argues that blinding integrity is rarely assessed in trials of drugs with noticeable effects, citing a review in which only 30% of 112 psychedelic and ketamine trials assessed it, and recommends asking patients what they guessed, why, and when. JCP → psychiatrist.com/jcp/functio… #ClinicalTrials #Psychopharmacology #JCP

Post attachment